On May 6, 2025, Koninklijke Philips NV reported Q1 2025 sales of EUR 4.1 billion, reflecting a 2% decline mainly due to decreased performance in China, but saw a 2% increase in comparable order intake. Major expenditures included EUR 1.025 billion related to the Philips Respironics recall, resulting in a free cash outflow of EUR 1.091 billion for the quarter.